<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bevacizumab treatment is associated with an increased risk of <z:hpo ids='HP_0000822'>hypertension</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HTN</z:e>), a potential marker for effectiveness </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to assess whether grades 2-3 HTN during bevacizumab treatment was associated with increased overall survival (OS) or progression-free survival (PFS) </plain></SENT>
<SENT sid="2" pm="."><plain>One hundred and eighty-one patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), who were treated in our Department from January 2009-February 2011 were included </plain></SENT>
<SENT sid="3" pm="."><plain>Bevacizumab was administered jointly with standard first- or second-line chemotherapy protocols </plain></SENT>
<SENT sid="4" pm="."><plain>Blood pressure was measured before each treatment </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HTN</z:e> was graded using common toxicity criteria </plain></SENT>
<SENT sid="6" pm="."><plain>There were 181 CRC patients </plain></SENT>
<SENT sid="7" pm="."><plain>Grades 2-3 HTN developed in 81 patients (44.75 %) but not in 100 patients (55.25 %); no patient developed grades 4-5 HTN </plain></SENT>
<SENT sid="8" pm="."><plain>Median follow-up was 15.2 months </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HTN</z:e> was associated with better OS in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HTN</z:e>-positive versus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HTN</z:e>-negative patients (median not reached vs. 36.8 months, p = 0.029) and better PFS (29.9 vs. 17.2 months, p = 0.024, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>Bevacizumab-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HTN</z:e> may represent a biomarker for clinical benefit in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients </plain></SENT>
</text></document>